Swedish biotech AnaCardio secures $70.9M Series B to advance heart failure drug
read at Endpoints ↗DealPositive
Swedish biotech AnaCardio announced a Series B financing round that raised €62.5 million ($70.9 million).
The capital will be used to move its chronic advanced heart failure drug toward registrational development, with the goal of demonstrating a safer profile.
The funding provides the Stockholm-based company with a runway extending well beyond the immediate development milestones.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Swedish biotech AnaCardio raises $70.9M to advance 'safer' heart failure drug”
read at Endpoints ↗85 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that